Use of methylphenidate and risk for valvular heart disease: A case-control study nested in the BIFAP cohort.

In this first-ever population-based study on this issue, association between methylphenidate and the incidence of VHD among persons in the 5 to 25 years age range was neither confirmed nor excluded. Additional studies may be required to clarify the presence or absence of this relationship.